Chinese Journal of Blood Purification ›› 2025, Vol. 24 ›› Issue (07): 590-593.doi: 10.3969/j.issn.1671-4091.2025.07.010

Previous Articles     Next Articles

Research progress in the use of anticoagulants during continuous renal replacement therapy for shock patients with low tissue perfusion and high risk of bleeding

ONG Chun-yan, LI Rong, TANG Si-yan, TANG Si-wei, BAI Ming, ZHANG Peng   

  1. Graduate School of Xi'an Medical University, Xi'an 710068, China; 2Department of Nephrology, Xijing Hospital, Air Force Military Medical University, Xi'an 710032, China; 3Department of Nephrology, Shanxi Provincial People's Hospital, Xi'an 710068, China
  • Received:2025-02-11 Revised:2025-03-10 Online:2025-07-12 Published:2025-07-12
  • Contact: 西安 710068,3陕西省人民医院肾脏内科 E-mail:zhangpeng@fmmu.edu.com

Abstract: Continuous renal replacement therapy (CRRT) is a common treatment for acute kidney injury (AKI), especially for patients with shock and tissue hypoperfusion. CRRT can effectively remove various kinds of toxins, maintain the balance of water and electrolytes, and stabilize hemodynamics in these patients. However, due to the continuous blood circulation and filtration during CRRT, the risk of thrombosis is increased, and anticoagulation is therefore necessary. Anticoagulation strategy is particularly complex in patients with shock combined with tissue hypoperfusion and high risk of bleeding, which needs to consider the balance between the effect of anticoagulants and the risks of bleeding and thrombosis. In this article the authors summarize the feasibility and safety of non-anticoagulation, citrate, nafamostat mesylate, argatroban and other common anticoagulation regimens used in CRRT for shock patients with low tissue perfusion and high risk of bleeding.

Key words: Continuous renal replacement therapy, Shock with tissue hypoperfusion, High risk of bleeding, Anticoagulation

CLC Number: